Johnson & Johnson Raises Full-Year Guidance
16 Abril 2019 - 8:53AM
Dow Jones News
By Kimberly Chin
Johnson & Johnson raised its full-year financial targets on
Tuesday as it reported sales strength in its pharmaceutical
division, though the company had a weaker showing in its other
segments.
The New Jersey-based company anticipates adjusted earnings this
year to be between $8.53 to $8.63 per share, up from its prior
forecast of $8.50 to $8.65 a share. It expects operational sales to
be between $82 billion and $82.8 billion, up from $81.6 billion to
$82.4 billion as previously targeted.
Sales in its pharmaceuticals division in the U.S. rose 4.1% in
the first quarter to $10.24 billion, driven by sales from its
multiuse treatment Stelara, its blood-disease treatment Imbruvica,
and the multiple myeloma treatment Darzalex. Imbruvica and Darzalex
both received regulatory approvals in the prior quarter.
Meanwhile, sales in its other divisions declined. Revenue from
its consumer segment fell 2.4% to $3.32 billion. Sales in its
medical devices business also fell 4.6%.
Overall sales were flat from a year ago at $20.02 billion though
it was still ahead of analysts polled by Refinitiv's expectations
of $19.61 billion.
Shares rose 1.2% in premarket trading.
J&J's profit fell 14% from the year-ago quarter to $3.75
billion, or $1.39 a share. Analysts expected earnings of $1.67 a
share.
J&J made $2.10 an adjusted share, missing analysts'
estimates by 7 cents.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
April 16, 2019 07:38 ET (11:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024